Please login to the form below

Not currently logged in
Email:
Password:

Voltarra names new CEO

Richard Becker has experience at Alcon, Merck, Novartis, OSI, Bayer and BASF

Voltarra Pharmaceuticals has appointed Richard Becker as CEO.

Becker brings more than 20 years' experience to the US biopharma, including senior commercial roles at Alcon, Merck, Novartis, OSI, Bayer and BASF.

In his new role, he leads a company with a pipeline of drugs for rheumatology, central nervous system oncology and immunology.

Voltarra's lead product is VOLT01, which is in late-stage trials for the treatment of osteoarthritis.

Becker said: “The broad portfolio will allow Voltarra Pharmaceuticals to capitalise on development synergies and favourably position the company with external customers. We are extremely excited about the pipeline as well as future plans for a partner in taking VOLT01 to the next stage.”

19th November 2013

From: Sales

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics